TIDMDMTR
DeepMatter Group PLC
21 October 2021
21 October 2021
DeepMatter to trial its DigitalGlassware(R) platform with
Aurigene Pharmaceutical Services
DeepMatter Group Plc (AIM: DMTR, "Deepmatter", the "Group"), the
international digital chemistry data company, has signed a trials
agreement with Aurigene Pharmaceutical Services Limited ("Aurigene
Pharmaceutical Services"), based in Hyderabad, India, to supply its
DigitalGlassware(R) platform.
Aurigene Pharmaceutical Services is a fully integrated Contract
Research, Development and Manufacturing Organization (CRO/CDMO)
providing a wide range of services for small and large
molecule.
DeepMatter will provide its DigitalGlassware(R) platform to
Aurigene Pharmaceutical Services to help screen, develop and scale
up chemistry procedures and to accelerate custom drug discovery and
development projects.
Aurigene Pharmaceutical Services seeks to evaluate the
technology to find efficiency and productivity gains through deeper
data insights via collated aggregated data streams to better
understand difficult synthetic routes and to foster active data
sharing capabilities. The technology will help scan every reaction
parameter and accelerate failed reaction diagnostics. Through this
project Aurigene Pharmaceutical Services reinforces its focus to
provide faster and efficient chemistry services to its customers
and thus accelerating the drug discovery and development
process.
DigitalGlassware(R) comprises a cloud-based software platform
allowing scientists to easily bring together digitised synthesis
protocols (recipes) and contextualised time-course sensor streams
from a range of analytical instrumentation, in real-time (see note
to editors below).
Mark Warne , CEO of DeepMatter, commented:
" This paid for trials agreement is another positive step in our
strategy to provide our DigitalGlassware(R) platform to the major
global Contract Research Organisations (CRO's) where the ability to
reproduce is paramount in order to accelerate the discovery of new
drugs.
Ravi Venkataraman, CEO of Aurigene Pharmaceutical Services
commented:
" Aurigene Pharmaceutical Services is committed to leveraging
cutting edge technologies to accelerate drug discovery and
development, and providing differentiated services to our clients
to bring new medicines to market. Digital transformation leveraging
Artificial Intelligence (AI)/Machine Learning (ML) tools is a key
focus area and our collaboration with DeepMatter is one step
towards faster patient centric innovation"
For more information contact
DeepMatter Group Plc
Mark Warne, Chief Executive Officer 0141 548 8156
Canaccord Genuity Limited (Nominated Advisor and Broker) 020
7523 8000
Bobbie Hilliam
Meare Consulting 07990 858548
Adrian Duffield
About DeepMatter Group plc
DeepMatter is building a unique, fully integrated digital
chemistry cloud platform of chemical reaction data for scientists,
who are working on early-stage chemical discovery &
development.
DeepMatter is integrating technology with chemistry to enable
scientists, principally in the commercial sector, to easily perform
and optimise chemistry. It is building, structuring and analysing
chemical reaction databases and using this substantial data for
real-time innovation and productivity gains in the chemical
industry - particularly pharmaceutical companies engaged in
pre-clinical drug discovery & development. This data is also
now enabling Artificial Intelligence (AI) driven chemical
automation
Times-course sensor data being the measuring of the effects of
chemical reactions over the course of time, providing faster
actionable insights that result in scientific breakthroughs.
Visit: www.deepmatter.io and follow @deepmattergroup
About Aurigene Pharmaceutical Services Limited
Aurigene Pharmaceutical Services is a leading contract research,
development and manufacturing organization ( CDMO ). Built on the
legacy of accelerating innovation and backed by a vast CDMO pharma
services experience in drug discovery , development and
manufacturing our mission is to relentlessly work for the success
of our clients and to build long-term relationships through a
holistic approach to accelerate the journey of a molecule from the
laboratory to market. By providing access to our resources,
knowledge and experience, we create success for our clients and
ultimately patients. As a CDMO pharma company we offer integrated
and standalone services for discovery chemistry, discovery biology,
development and manufacturing services for clinical phase I-III
programs, regulatory submission batches and commercial
manufacturing. A differentiating factor as a pharmaceutical
contract manufacturing organization is the integrated API and
formulations service that spans from key starting material,
advanced intermediates, APIs to finished products such as oral
solids, sterile products, nasal solutions etc. Our development and
pharmaceutical API manufacturing services in India are complemented
by cGMP commercial manufacturing facilities in the UK, Mexico, USA
and India.
Aurigene is an independently managed wholly-owned subsidiary of
Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY,
NSEIFSC: DRREDDY).
For more information, log on to: www.aurigeneservices.com or
Email: ContactAPSL@aurigeneservices.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGLBDGXUDDGBB
(END) Dow Jones Newswires
October 21, 2021 03:00 ET (07:00 GMT)
Deepmatter (LSE:DMTR)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Deepmatter (LSE:DMTR)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024